Thank second you, XX% report quarter $X.X up of basis on pleased billion, XX% We're and reported revenue Joe. to organically. a
and businesses, very second sequential growth in nice our more nice we're recovery XXXX. and quarter XXXX seeing in importantly, year-to-date a at performance, Looking all our
you from As most our had current it's this to this that Therefore, a benefits point comparison. recall, quarter impact year, business being second negative impacted. with quarter out COVID-XX last on important XXXX
QX to to and towards normal. by continue general, steady to and the market recovery, to delta If varies Similar commerce countries emergence to we're recovery market turn the helpful you U.S., a teams pre-pandemic today last the country. date, of might of Slide In challenges thought appears impacting the continue it are year, to variant to despite COVID-XX that XXXX our face outside recovery. you XXXX. U.S., of and seeing certain be towards during back But our a with business our starting compares segment. X, to COVID-XX my on of trending how the which to -- order believe progress stabilize in sense and give good the the be for To our a color life performance be execute others in strategy, we recovery. by type I pace with minute recovery. we a provide the comments levels. some of spend B&L and I addressing on As to want QX reference our
$XXX of up million revenue within All growth quarter XX% this organically. contributed Second the was segment to our B&L businesses quarter. the
business. turning Now Care Vision the to Global
of and and of Second second quarter overall U.S. contributor Vision XX% ULTRA demonstrates the The revenue the growth XXX% market, for organic of Europe. steady which up The brand, coming organically. INFUSE, with the market quarter Biotrue International success XX%. recently and International launched that ONEday, key quarter. SiHy in ULTRA with coupled in recovery in the SofLens Vision U.S. in up family $XXX Care. in from U.S. growth growth million parts the recovery a up the XX% was ONEday in in was mainly was participate growth international contributors our the of Care reflects Asia and Biotrue were the the all to we key the
expect imposing way pleased to with return the growth to new gradually pre-COVID of International note face the do COVID-XX pre-pandemic and restrictions. are growth some we're levels, it's challenges this with to not While our rates. all countries to levels of continuing We important we're business to Vision that back Care quarter,
to on Global Moving our Surgical business.
XXX%. steady business compared up strength and growth reference our in international To recovery. you was of organically, Second Europe. second and performance. by U.S. to growth quarter international U.S. driven the regarding with surgical Both interior point a up a with all as reflects The XX% XX% provide were the up disposables recovery, our revenue million by regions of quarter recovery in surgical the market was current led in with performance XXXX Asia organically quarter and X% $XXX the
Consumer. Global our to Turning
growth $XXX commercial consumer with consumer a X% and pleased in strong XX% consumer the LUMIFY the in organically PreserVision, Second consumer up the quarter growth coupled Ocuvite the million was U.S. down and business performance. business business business. in We're our U.S. revenue vitamins, was U.S. execution with up eye very with strong X%. The international driven of
half driven in year-to-date, favorably XXXX, a solid For consumer the the impacted was of recall business current mainly by down International pantry was Europe. consumer which by quarter organically, and growth against strong loading. U.S. demonstrated product X% first the
of line trajectory. growth growth. Overall, with well, global international continued business U.S. consumer to impact a business the product the consumer recall, the perform was healthy the Excluding with in growth consumer business gaining share the market
of quarter impact the X% roughly current product the recall, performance. XXXX quarter Excluding second performance was to the as compared organically
second quarter We've revenue MedD XX% postponed quarter quarter to VYZULTA. XXXX. eye due a in Finally, last volumes XXXX brands, VYZULTA SM. $XXX for The SM and for current expanding and driven a promoted comparison Rx benefited B&L, growth versus and the LOTEMAX organically business to quarter second due the surgeries in making being The higher COVID-XX. was Ophtho of million quarter PROLENSA, of to soft access was from year in our key steady progress Besivance, second by LOTEMAX coverage been up
Although current growth the saw second and rebates, the quarter improved XX% VYZULTA access continue trajectories. In will SM position versus XXXX. level VYZULTA this LOTEMAX both the TRx increases impressive of growth a TRx to quarter
of be Rx was factor continue LOEs from XXXX, was versus and on LOTEMAX XX%. to Finally, versus prior a big Ophtho a gel QX the portfolio, quarter drag year which continued erosion U.S LOE down our
Salix. to turning Now
consumption increase volume year drain of experienced increase XX%. was XIFAXAN, was Performance COVID. the that Second up was remainder QX result by driven a with quarter of the retail million XX%; XXXX XX% was up as due up in end the volume, and $XXX and inventory up revenue all of to The wholesale was a increased XX% nonrecurrence and XIFAXAN increase due the RELISTOR the from due the to QX TRULANCE XXXX. XX% mainly of of was X/X was that to then we last
direction. our the XIFAXAN of in our trends and with As trends. certainly TRx QX moving of in end the levels line historical right XXXX, expectation were are inventory
COVID-XX impacted long-term As we care setting. has quarters, in prior Rxs the in discussed negatively
trend prescriptions was in lag, Despite business with driven TRULANCE by expect the the care have growth for not While we're levels. overall, within pre-COVID-XX to volume. XX% and prescriptions recovered the sequential long-term recovery the The mainly channel rebound. fully long-term this we care will XIFAXAN pleased increase
reference, recall, of you about TRULANCE, with good Uceris XXXX volume a quarter up despite we point X% the ago, Salix impact mass Overall, we the about business. to care as pre-COVID to Apriso current feel year growth LOEs. wins us and within for meaningful several levels you If recovery provide second growth. of compared was the helped trajectory Rx drive secured trends To the and performance core a and our which
the business current in impacts, quarter QX XXXX. the as the LOE grew X% compared of organically to base Excluding Salix
to segment. International Now turning the Rx
segment. Rx up pricing. by lower led organically, mainly offset of partially of growth XX% revenue for the realized million Second International driven Poland quarter net XX%, and $XXX was volumes higher by Europe the
Moving segment. Derm to Ortho
was delivered Second quarter mainly million another global quarter impressive The Thermage growth FLX realized with strong to an mainly medical business XX% growth U.S. revenue lower $XXX China Solta of pricing. down organically. net business declining XX% up in on trend and The assets organically, demonstrate the continues by LOE XX% organically. driven derm was of
Finally, our Diversified segment.
revenue of Second organically. quarter was down $XXX million X%
business due LOE Neuro X%. Ativan was growth by The decline in was partially to Our and down Aplenzin. assets offset
factor with our generics pricing the the biggest Our the of entered and generic business market net volumes erosion additional organically natural as of was down competitors XX% products. being
impacts. ARESTIN organically from strong year as COVID-XX posted dentistry Finally, XXX% it prior by driven growth rebounds
favorable versus Turning by of businesses Slide points gross We is a already I'll higher now to improvement on year-over-year margin, the as to start volume covered a comparison. profit. result with favorable was with the which from All favorable gross revenues, X. our contributed sales variance the so in XXXX. profit Gross coming XX QX basis core margin manufacturing P&L
beyond. the our full gross versus XX%. and our operating $XXX in were factors within be to in promotional Within an to market adjusted enabled for trajectory to We margin expected as QX the chain, COVID-XX support efforts guidance and costs to identify This other by on expenses, resources impacts. unfavorable XXXX, XXXX sales our continue redeploy recovers growth supply XXXX. basis, operating our Note to is implement SG&A and global million represents absorb roughly which mix our efficiencies us that year
projects. our If for full OpEx QX negatively impacted you of XXXX expectation XXXX expectation from performance $X.X year trend. restrictions, said, last by for second our $XXX recall, roughly roughly by as gradually for rate half we're $XXX roughly expectation our which We for reducing second updating from reflect That key $XXX and million required basis year. our our full current spend Keep a consumer the continued million more do from expect that COVID-XX a R&D adjusted billion negatively recall XXXX. in SG&A in currency the mind of billion future $X.XX X% the the quarter, in by that Adjusted the normalized to of pipeline on increase quarter That to year EBITDA we us constant year dramatically run the up to R&D reduce the supporting EBITDA XXXX business. to return XXXX. increased will XX% spend spend said, trajectory impacted million. of our full to we're was compared roughly for as product to to quarter was QX in
current quarter XX%. is Our adjusted EBITDA in margin the
Excluding run adjusted our rate XX%. have of been our EBITDA in of recall, with normal the the would impact margin line
EBITDA Looking margin approximately full our forward XX%. do to expect to be the year, adjusted we
Turning X. to Slide
separation-related of a from $XXX million. liabilities, and operations from sum During generated the the cash was legacy GAAP for quarter, basis. legal we cash Adjusted divestiture of the costs, Amoun generated operations million $XXX on
very are guidance we're cash generation the adjusted generation the cash billion. year-to-date. roughly year $X.X billion strong the our in full roughly for pleased updating $X.X to quarter and We the with for Therefore, from
Turning X. to Slide
to progress make debt very continue in We paydown. our nice
repaid quarter, $XXX to our debt million from million. debt we with During operations, of $XXX repayment the bringing cash year-to-date second
repayment. bringing strong focus We're cash leverage $XXX in billion. reduction cash additional net effective has of a today, we our close, recovery quarter X, last year, and X.X repaid commitment bringing an we divestiture, announced today to and our And X.Xx in QX. this of $X.XX continuing have ratio hand September Furthermore, whole the debt operations. Amoun debt with on total repaid debt, planned year-to-date million QX million will accomplishment, repayment debt as connection Xx using decline $XXX aggregate to last of we today quarter cash our from $X.X bonds year-to-date of on with proud the of progress to Our a to our $XXX our reducing XXXX, from with of combined very operations, from turn drove redemption After debt from million on to billion.
to Something keep in mind.
XXXX we're looking half we in While still leverage XXXX exceptionally so due rapid far, second our decline pleased in don't Recall, such from QX debt and half the the expect COVID-XX, to to our our progress a second spend. EBITDA our on to reducing negative XXXX. forward, down see with in of had an impact low began of recover we while very pay ratio the OpEx
and As the impact EBITDA coupled such, and the from QX half strong XXXX, second leverage QX our with will down. pay ratios anticipated legal XXXX debt settlement,
we until debt of debt or make don't X, leverage any maturities. mandatory continue our nice to of remainder the have For we with as our net On our XXXX, leverage we X.Xx to expect we amortization have Slide increase slightly versus today, maturities remain today. or payments And flat progress XXXX.
the EBITDA closing; updating contribution the of new $XXX X relative XX. loss EBITDA it second, to also Now following the Today, guidance guidance million. XX million; result million year revenue of to is it guidance of and July billion reflects reflects it by reflects Slides full factors: to roughly our and reflect range currency XXXX of $X.X change This on the $XXX the guidance to the $XX to unfavorable unfavorable we $XX billion. XX for million May in revenue movement of our guidance We're of recall $X.X First, a Amoun third, impact Amoun of of for our product $XX of million turning our revised million. adjusted $XX movements the from currency
$XX $X.X the million $X.XX product guidance to after absorbing billion the of revised impact recall. even for the EBITDA adjusted of billion, in range Our roughly is
also assumptions our addition, number updated a we In key on Slide guidance XX. of
Joe. Now back to you,